Faglig opdatering fra EHA og ICML 2025

Vi har fornøjelsen af at kunne give en opdatering fra de to spændende kongresser EHA og ICML, som fandt sted i henholdsvis Milano og Lugano i juni 2025. 

Værterne i videoerne er:

  • Agoston Gyula Szabo, Afdelingslæge, Afdeling for Blodsygdomme, Rigshospitalet
  • Professor Martin Hutchings, MD, Phase 1 Unit, Copenhagen University Hospital, Denmark 
     


VIDEO 1: I denne video gennemgås data fra EHA 2025

VÆRT: Agoston Gyula Szabo, Afdelingslæge, Afdeling for Blodsygdomme, Rigshospitalet 

  • Jagannath et al, S192 Long Term (>5 years) Remmision and Survival after treatment with ciltacabtagene autoleucel in CARTITUDE-1 Patients with R/R MM
  • Popat et al, EHA 2025, (S100) First-in-human study of JNJ-79635322 (JNJ-5322), A novel, next-generation Trispecific Antibody, in patients with relapsed/refractory mulitiple myeloma: Initial Phase 1 Results.
     


VIDEO 2: I denne video gennemgås data fra EHA 2025

VÆRT: Agoston Gyula Szabo, Afdelingslæge, Afdeling for Blodsygdomme, Rigshospitalet

  • Dimopoulos et al, EHA 2025, S206: MAGNETISMM-6
  • Avet-Loiseau H, Davies FE, Samur MK, Corre J, D'Agostino M, et al., International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma.
     


VIDEO 3: I denne video gennemgås data fra EHA og ICML 2025

VÆRT: Professor Martin Hutchings, MD, Phase 1 Unit, Copenhagen University Hospital, Denmark. 

  • Melchardt et al, Frontline Phase II Rituximab-Polatuzumab-Glofitamab Trial, Abstract no. S248, EHA, Milano, 2025
  • Alderuccio et al, LONCASTUXIMAB TESIRINE PLUS GLOFITAMAB IN PATIENTS WITH R/R DLBCL, Abstract no. 78, ICML, Lugano, 2025
     


VIDEO 4: I denne video gennemgåes data fra EHA og ICML 2025

VÆRT: Professor Martin Hutchings, MD, Phase 1 Unit, Copenhagen University Hospital, Denmark.

  • Matehew Ku et al, A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (CAR) T-cell Therapy in Patients With Relapsed/Refractory Larbe B-Cell Lymphoma, Abstract no. S239, EHA, Milano, 2025
  • Updates on ICML workshop on molecular profiling of DLBCL.